SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices approach all-time highs, fueled by speculation around potential Fed rate cuts and renewed interest in precious metals as a hedge against economic uncertainty. Community members are discussing technical breakouts, potential for a silver squeeze, and historical inflation-adjusted valuations, while some express concerns about market manipulation and potential pullbacks. The broader context involves increased industrial demand for silver and its role as a safe-haven asset amid global economic concerns.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is gaining attention as users discuss the potential of earning crypto through physical activity. Community members highlight the project's long-term potential and token burn events, while others suggest it's currently undervalued. Discussions also revolve around the mechanics of earning $SWEAT and its availability on various exchanges.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne ($S) is garnering attention as investors debate its valuation and potential for growth within the cybersecurity sector. Community discussions revolve around upcoming earnings and whether it will trigger a breakout, with some speculating on a potential buyout given its perceived undervaluation compared to competitors. Despite positive developments, concerns linger around management and consistent profitability.

Global X Funds - Global X Funds Global X Robotics & Artificial Intelligence ETF

Global X Funds Global X Robotics & Artificial Intelligence ETF

$BOTZ is trending as investors weigh the potential of AI and robotics against concerns of a possible tech bubble and broader economic weakness. Discussions revolve around the ETF's key holdings, including NVDA, and its exposure to the US-China AI arms race, with community members analyzing its long-term growth prospects.

SPDR Series Trust - State Street SPDR S&P Oil & Gas Exploration & Production ETF

SPDR Oil & Gas Exploration & Production ETF

XOP is trending amid geopolitical tensions and shifting supply dynamics, with potential impacts from Iranian oil exports and OPEC+ production decisions driving market speculation. Community members are weighing the possibilities of further output cuts and debating the sector's undervaluation. Bullish investors are monitoring the ETF for potential breakouts, while others are cautious about demand in China and wider economic factors.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley ($MS) is trending amid discussions around bank regulations, potential M&A activity, and analysts weighing in on its financial outlook and strategic shifts. The community is focused on institutional ownership, potential earnings catalysts, and its position relative to competitors like Goldman Sachs ($GS). Recent news includes Morgan Stanley expanding crypto access and analysts adjusting price targets, driving both bullish and bearish sentiment.

SSgA Active Trust - Health Care Select Sector SPDR

Health Care Select Sector SPDR Fund

The Health Care Select Sector SPDR Fund ($XLV) is trending amid discussions of sector rotation and potential breakout opportunities, particularly as some analysts suggest a shift from technology into healthcare. Community members are actively trading call options on XLV, targeting higher price levels, while also weighing in on potential impacts from healthcare policy and individual companies within the sector. There is also discussion that a recent top may need to be retested.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as the community discusses its long-term potential, interoperability and recent supply cap implementation.  Some investors view it as a solid project for cross-chain applications, while others are weighing its potential against emerging Layer 1 solutions focused on high-speed settlement and compliance.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

OXLC is trending as investors weigh the impact of high dividend payouts and a recent reverse stock split. Community discussions revolve around the stock's potential for recovery, with some expressing concerns about long-term price erosion and others highlighting the potential for high yields if the dividend remains stable. Broader market factors, like interest rate decisions and sector-specific news, are also influencing investor sentiment.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is trending as traders discuss potential breakouts and a possible shift in global market dynamics favoring Chinese equities amid trade discussions. Bullish sentiment is fueled by signals of government support and potential for policy easing, while some analysts point to oversold conditions and attractive valuations compared to US tech. Community members are actively trading options and discussing key price levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Value Stocks to Buy for May 28th

New Strong Buy Stocks for May 28th

Shares of Phio Pharmaceuticals Corp. (PHIO) traded 63% higher on Wednesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://phiopharma.com/phio-pharmaceuticals-announces-positive-safety-monitoring-committee-recommendation-to-advance-intasyl-ph-762-skin-cancer-study-to-fourth-dose-escalation-cohort/">announced</a> that a Safety Monitoring Committee (SMC) recommended escalating the dose in the clinical trial for its lead product candidate, PH-762.The dose-escalating clinical trial aims to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in certain skin cancers. The trial assesses tumor response and determines the recommended dose for further study of the product candidate.PH-762 is an Intasyl compound that silences the PD-1 gene implicated in various forms of skin cancer.CEO Robert Bitterman said the company is optimistic the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.The company said that two of four patients diagnosed with cutaneous squamous cell carcinoma and enrolled in the second cohort of the trial had 100% tumor clearance upon excision.While one had a 90% tumor clearance, the fourth patient maintained stable disease, the company said.Three patients were enrolled in the third cohort of the trials. The injections were well tolerated with no serious adverse events, the company said.On Stocktwits, retail sentiment around Phio Pharmaceuticals rose from ‘bearish’ to ‘extremely bullish’ while message volume jumped from ‘high’ to ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:1298/298;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_09_at_1_47_54_PM_png_f2666fba4f.webp" alt="PHIO's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 9, 2025 | Source: Stocktwits" width="1298" height="298"><figcaption>PHIO's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/PHIO">PHIO shares</a> rose as high as $2.73 on Wednesday before paring gains to around $1.50.The stock fell by over 13% this year and by over 73% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pacbio-plans-to-reduce-spending-over-nih-funding-uncertainty-tariffs/chfnXrfRbBd">PacBio Stock Soars On Plans To Reduce Spending Over NIH Funding Uncertainty, Tariffs: Retail Is Overjoyed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer. 

Equity

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin cancer.

Shares of Phio Pharmaceuticals Corp. (PHIO) nearly&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/phio-stock-rockets-on-cancer-trial-data/chGNgCORNj">quadrupled</a> on Monday after the biotech firm announced promising results from its Phase 1b trial for the cancer immunotherapy PH-762, designed to enhance the immune system's ability to target tumors.However, the nanocap stock reversed course on Tuesday, plunging over 50% following news of a registered direct offering.Phio revealed agreements to sell 1.1 million common shares at $3 each, with a concurrent private placement issuing short-term warrants to purchase 2.1 million shares at the same price.&nbsp;The combined transactions are expected to generate approximately $3.2 million in gross proceeds, earmarked for working capital and other corporate purposes.Despite the sharp decline, retail investors remain optimistic, as evidenced by a Stocktwits poll where nearly 50% of over 900 participants believe the stock has "more room to run."&nbsp;Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.Retail sentiment on Stocktwits turned 'extremely bullish' on Tuesday, with many users predicting a post-offering rally fueled by Phio's low float and the potential of its drug pipeline.&nbsp;Some highlighted the company's ongoing trial progress, while others saw the price drop as a buying opportunity.<stembedurl>https://stocktwits.com/pragash2094/message/599992949</stembedurl><stembedurl>https://stocktwits.com/HUBC1/message/599986181</stembedurl><stembedurl>https://stocktwits.com/TrendIsMyFriend/message/599998502</stembedurl>Like many early-stage biotech firms, Phio has yet to generate revenue. However, its latest financial report showed narrowed losses of $1.5 million for the quarter ended Sept. 30, compared to $2.8 million a year earlier.&nbsp;The company reported $5.4 million in cash, down from $8.4 million a year earlier but more than $4.7 million at the end of the previous quarter.The stock has lost nearly 50% of its value over the past year but has seen retail interest soar. The number of new followers on Stocktwits jumped by over 9%, while message volume increased more than 1,600-fold.With a short interest of 3.8% and ongoing developments in its PH-762 trial, retail investors remain laser-focused on updates about higher-dose concentrations and further enrollment milestones.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Phio’s stock has lost nearly 50% of its value over the past year but has seen retail interest soar. | Image source: Maria Korneeva on Getty Images

We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run

Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.

Shares of Phio Pharmaceuticals Corp. surged 330% Monday afternoon, reaching their highest levels in nearly eight months, to become the top gainer across U.S. bourses.&nbsp;This explosive move followed the announcement of positive results from a Phase 1b trial of its cancer treatment, PH-762, which is designed to enhance the immune system’s ability to target tumors.&nbsp;Trading volume soared to over 220 times the daily average, drawing significant attention from retail investors.Phio revealed that patients in the second cohort of its ongoing trial exhibited these pathologic responses: Two patients with cutaneous squamous cell carcinoma experienced a complete response (100% tumor clearance); one patient had a partial response (90% tumor clearance); one patient maintained stable disease, with no progression.The trial focuses on evaluating PH-762 for neoadjuvant use in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.&nbsp;Importantly, no dose-limiting toxicities or clinically relevant adverse events have been reported, and the intratumoral injections have been well tolerated, the company said.Mary Spellman, Acting chief medical officer of Phio, expressed optimism about the tumor responses, saying, “We look forward to continued enrollment which will permit assessment of higher dose concentrations of PH-762.”&nbsp;"These positive results in the early stages of dose escalation offer promise for our vision, 'striving for a cancer free future' using INTASYL technology" said CEO Robert Bitterman.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PHIO_sentiment_meter_and_message_volume_Jan_13_38cb5ff222.png" alt="PHIO sentiment meter and message volume Jan 13.png" width="1318" height="324"><figcaption>PHIO sentiment meter and message volume Jan 13 as of 12:15 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Phio spiked to 'extremely bullish' levels, with users sharing optimistic price targets and success stories.<stembedurl>https://stocktwits.com/M105/message/599814732</stembedurl><stembedurl>https://stocktwits.com/Ian980/message/599806765</stembedurl><a href="https://stocktwits.com/symbol/PHIO">Phio’s stock</a> has gained nearly 15% over the past 12 months, with Monday’s rally marking a sharp shift in momentum.&nbsp;Investors are closely watching for further enrollment updates and results from higher dose concentrations in the ongoing trial.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The trial focuses on evaluating PH-762 for neoadjuvant use in Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. | Image source: Getty Images

Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated

CEO Robert Bitterman highlighted the potential of Phio’s proprietary INTASYL RNAi technology, which targets proteins that hinder the body’s immune response to cancer.

Phio Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying

Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?

Phio Pharmaceuticals unveils findings on PH-762, a promising candidate for cancer therapy. Discover its rapid cell uptake and tumor-inhibiting potential.
read more...

National Spotlight Features Phio's Innovative RNAi Technology Platform

Program will be airing on PBS with Dennis Quaid in April It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp...

Phio Pharmaceuticals reports FY23 EPS ($5.20) vs ($10.10) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

Four sites across the country participating in clinical trial for lead product candidate PH-762 Two patients have already completed treatment New patent granted for skin related treatments...

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Phio Pharmaceuticals Corp

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

PHIO
Phio Pharmaceuticals Corp

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PHIO News

PHIOPhio Pharmaceuticals Corp